Search
Close this search box.

Daily Pill with Chemotherapy Shows Promise in Shrinking Pancreatic Tumors in Early Trial

Barcelona:A daily pill combined with chemotherapy has shown potential in shrinking tumors in patients with advanced pancreatic cancer, as evidenced by an early clinical trial. Researchers found that the treatment led to tumor shrinkage in approximately 60% of the participants.

According to Anadolu Agency – English, the trial tested the targeted medicine daraxonrasib alongside chemotherapy in 61 patients whose pancreatic cancer had metastasized. None of the patients had received prior treatment for their metastatic disease. The results were shared at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

The study, sponsored by Revolution Medicines, reported that 60.7% of the patients experienced a confirmed response, with tumors either shrinking or becoming undetectable. Furthermore, five patients, or 8.2%, showed a complete response with no detectable tumors on scans. Researchers, however, noted that the absence of detectable tumors does not imply a cure. The disease control rate, encompassing stable or reduced tumor size, was 90.2%. The median progression-free survival was reported at 12.8 months after a median follow-up of 18.3 months.

Despite the positive outcomes, researchers emphasized the trial's limitations, including its small size and lack of randomization compared to chemotherapy alone. Shivan Sivakumar, a professor at the University of Birmingham, described the findings as "very encouraging," though he cautioned that it is yet unclear if these results will lead to longer overall survival.

A larger phase III trial, RASolute 303, is currently underway to assess daraxonrasib alone and in combination with chemotherapy against chemotherapy alone in patients with previously untreated metastatic pancreatic cancer. Daraxonrasib functions by inhibiting active RAS proteins, which are involved in cancer growth, with RAS mutations present in over 90% of pancreatic cancers.

In the early trial, patients received daraxonrasib alongside gemcitabine and nab-paclitaxel chemotherapy. Common side effects included rash, diarrhea, fatigue, and reduced blood cell counts, with about 5% of participants discontinuing treatment due to side effects linked to daraxonrasib. The US Food and Drug Administration approved daraxonrasib, marketed as Rasonque, for specific adults with metastatic pancreatic adenocarcinoma on August 26. The approval applies to patients who have undergone at least one previous systemic treatment or are ineligible for multidrug systemic therapy. The first-line combination evaluated in the study continues to be under investigation.